Success Metrics

Active Trials
1(33%)

Phase Distribution

Ph early_phase_1
3
100%

Phase Distribution

3

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution3 total trials
Early Phase 1First-in-human
3(100.0%)

Highest Phase Reached

Early Phase 1

Trial Status & Enrollment

Completion Rate

0.0%

0 of 1 finished

Non-Completion Rate

100.0%

1 ended early

Currently Active

1

trials recruiting

Total Trials

3

all time

Status Distribution
Active(2)
Terminated(1)

Detailed Status

Withdrawn1
Not yet recruiting1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
1
Success Rate
N/A
Most Advanced
Early Phase 1

Trials by Phase

Early Phase 13 (100.0%)

Trials by Status

withdrawn133%
not_yet_recruiting133%
recruiting133%

Recent Activity

1 active trials
Showing 3 of 3
withdrawnearly_phase_1

This is an Open-Label Study to Assess the Safety and Efficacy of GC012F in Patients With Multiple Sclerosis

NCT07364487
recruitingearly_phase_1

This is an Early Exploratory Study to Assess the Tolerability and Safety of GC012F in Patients With Multiple Sclerosis

NCT07303790
not_yet_recruitingearly_phase_1

An Open-label Study of GC012F in Rheumatoid Arthritis.

NCT07315503

Clinical Trials (3)

Showing 3 of 3 trials
NCT07364487Early Phase 1

This is an Open-Label Study to Assess the Safety and Efficacy of GC012F in Patients With Multiple Sclerosis

Withdrawn
NCT07303790Early Phase 1

This is an Early Exploratory Study to Assess the Tolerability and Safety of GC012F in Patients With Multiple Sclerosis

Recruiting
NCT07315503Early Phase 1

An Open-label Study of GC012F in Rheumatoid Arthritis.

Not Yet Recruiting

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3